Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.

IF 2.8 3区 医学 Q2 INFECTIOUS DISEASES
HIV Medicine Pub Date : 2024-12-10 DOI:10.1111/hiv.13748
Kate Alford, Shiraaz Sidat, Katherine Bristowe, Paola Cicconi, Jamie H Vera, Fiona Cresswell
{"title":"Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.","authors":"Kate Alford, Shiraaz Sidat, Katherine Bristowe, Paola Cicconi, Jamie H Vera, Fiona Cresswell","doi":"10.1111/hiv.13748","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The twice-yearly, long-acting lenacapavir (LA LEN) antiretroviral therapy (ART), when combined with an optimised background regimen, provides a subcutaneous injectable treatment option for people with HIV. This study aimed to understand the preferences, barriers and facilitators for uptake and implementation of LA LEN, with a view to informing clinical implementation.</p><p><strong>Methods: </strong>In-depth qualitative interviews and focus groups with purposively sampled people with HIV and healthcare workers (HCWs) from UK HIV services were conducted. Transcripts were analysed using summative and conventional content analysis.</p><p><strong>Results: </strong>Thirty-four people with HIV with varied ART experience were recruited from two HIV services. Participants included 22 (65%) identifying as cisgender men and 12 (35%) identifying as cisgender women; median age was 55 years (range 26-76 years). Fourteen HIV HCWs took part in three focus groups. Four key themes and 12 subthemes were identified: LA LEN as a treatment option; LA LEN versus oral ART; switching considerations; and administration of LA LEN. The majority (88%) of people with HIV were interested in switching to LA LEN if offered. Preference was markedly reduced if an oral ART pairing was required. Convenience of the dosing schedule, reduced pill burden and issues around stigma were reasons for interest in LA LEN, but concerns regarding efficacy, dosing interval windows, monitoring and side effects were described. HCWs felt the benefit of LA LEN was as a treatment option for those with adherence issues, drug resistance and a high pill burden. Broader use of LA LEN raised concerns over drug resistance, delivery capacity and storage.</p><p><strong>Conclusions: </strong>LA LEN was viewed as a preferable treatment choice for many people with HIV, provided an all-injectable regimen was available. Feasibility assessments for provision of injectable ART and research on its potential for self-administration are needed.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hiv.13748","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The twice-yearly, long-acting lenacapavir (LA LEN) antiretroviral therapy (ART), when combined with an optimised background regimen, provides a subcutaneous injectable treatment option for people with HIV. This study aimed to understand the preferences, barriers and facilitators for uptake and implementation of LA LEN, with a view to informing clinical implementation.

Methods: In-depth qualitative interviews and focus groups with purposively sampled people with HIV and healthcare workers (HCWs) from UK HIV services were conducted. Transcripts were analysed using summative and conventional content analysis.

Results: Thirty-four people with HIV with varied ART experience were recruited from two HIV services. Participants included 22 (65%) identifying as cisgender men and 12 (35%) identifying as cisgender women; median age was 55 years (range 26-76 years). Fourteen HIV HCWs took part in three focus groups. Four key themes and 12 subthemes were identified: LA LEN as a treatment option; LA LEN versus oral ART; switching considerations; and administration of LA LEN. The majority (88%) of people with HIV were interested in switching to LA LEN if offered. Preference was markedly reduced if an oral ART pairing was required. Convenience of the dosing schedule, reduced pill burden and issues around stigma were reasons for interest in LA LEN, but concerns regarding efficacy, dosing interval windows, monitoring and side effects were described. HCWs felt the benefit of LA LEN was as a treatment option for those with adherence issues, drug resistance and a high pill burden. Broader use of LA LEN raised concerns over drug resistance, delivery capacity and storage.

Conclusions: LA LEN was viewed as a preferable treatment choice for many people with HIV, provided an all-injectable regimen was available. Feasibility assessments for provision of injectable ART and research on its potential for self-administration are needed.

求助全文
约1分钟内获得全文 求助全文
来源期刊
HIV Medicine
HIV Medicine 医学-传染病学
CiteScore
5.10
自引率
10.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信